Related Experiment Video
Updated: Jun 21, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Radiation therapy for lymph node metastases from hepatocellular carcinoma
Ryo Toya1, Ryuji Murakami, Tadamasa Yasunaga
1Department of Radiation Oncology, Kumamoto University Hospital, Japan. ryo108@m9.dion.ne.jp
Hepato-Gastroenterology
|July 8, 2009
Summary
Radiation therapy (RT) effectively controls lymph node (LN) metastasis in hepatocellular carcinoma (HCC). Higher RT doses (≥58 Gy10) improve local response, though survival benefits require further study.
Area of Science:
- Oncology
- Radiation Oncology
- Hepatocellular Carcinoma Research
Background:
- Hepatocellular carcinoma (HCC) prognosis is improving, increasing the importance of managing lymph node (LN) metastasis.
- Lymph node metastasis is a critical factor in HCC progression and patient outcomes.
Purpose of the Study:
- To evaluate the treatment outcomes of radiation therapy (RT) for HCC-related LN metastases.
- To identify predictive factors for local control and survival in patients with HCC LN metastases treated with RT.
Main Methods:
- Retrospective analysis of 23 patients with HCC and LN metastases treated with RT.
- RT doses ranged from 28-56 Gy (BED 36-67.2 Gy10), with a median of 58.5 Gy10.
- Evaluation of response rates, local control, and survival, with analysis of predictive factors.
Main Results:
- An overall response rate of 83% (5 complete, 14 partial responses) was observed.
- Higher RT doses (≥58 Gy10) correlated with significantly better local response (P = 0.014).
- Median survival time was 19 months; liver tumor status was the sole independent predictor of survival.
Conclusions:
- RT is an effective modality for local control of LN metastases in HCC.
- Doses exceeding 58 Gy10 are recommended for optimal local response.
- While RT shows efficacy in local control, a direct survival benefit requires further investigation.
